



Verrica Pharmaceuticals Announces Participation in the Jefferies 2018 London Healthcare Conference

November 1, 2018

WEST CHESTER, Pa., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a pharmaceutical company focused on identifying, developing and commercializing innovative pharmaceutical products for the treatment of skin diseases with significant unmet needs, today announced that the company will participate in the Jefferies 2018 London Healthcare Conference.

Ted White, President and CEO, will present and provide a business overview of the company's pipeline programs on Wednesday, November 14, 2018 at 12:40 p.m. GMT.

A live audio webcast of the Jefferies 2018 London Healthcare Conference presentation will be available in the Investors/Events & Presentations section of the Verrica website at <http://www.verrica.com/>. A webcast replay will also be available on this website shortly after conclusion of the event for 30 days.

About Verrica Pharmaceuticals Inc.

Verrica is a pharmaceutical company focused on identifying, developing and commercializing innovative pharmaceutical products for the treatment of skin diseases with significant unmet needs. The company's lead product candidate, VP-102, is currently being evaluated in two Phase 3 clinical trials for the treatment of molluscum contagiosum and in a Phase 2 clinical trial for the treatment of common warts.

Contacts

Chris Degnan

Chief Financial Officer
484.453.3300 ext. 103
info@verrica.com

Patti Bank

Managing Director
Westwicke Partners
415.513.1284
patti.bank@westwicke.com



Source: Verrica Pharmaceuticals Inc.